Status:
COMPLETED
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
Lead Sponsor:
Sumitomo Pharma America, Inc.
Collaborating Sponsors:
Dainippon Sumitomo Pharma America
ICON Clinical Research
Conditions:
Overactive Bladder Syndrome (OABS)
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
Brief Summary
SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg...
Detailed Description
A multicenter study conducted in patients with OABS comprising a 2-week single blind placebo run-in period followed by an 8-week randomized, double-blind, placebo controlled treatment period with pati...
Eligibility Criteria
Inclusion
- Main
- Males, or females who are not of child-bearing potential
- Aged 20-80 years (inclusive) with a diagnosis of OABS based on symptomatic reporting over a period of 6 months (micturition frequency, and urgency with or without incontinence) prior to screening.
Exclusion
- Main
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT00409539
Start Date
December 1 2006
End Date
July 1 2008
Last Update
December 10 2014
Active Locations (69)
Enter a location and click search to find clinical trials sorted by distance.
1
Visions Clinical Research
Tuscon, Arizona, United States, 85712
2
Peninsula Urology Center
Atherton, California, United States, 94027
3
San Bernadino Urological Association Medical Group
San Bernadino, California, United States, 92404
4
9040 Friars Road
San Diego, California, United States, 92108